EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY 4.0

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

Patrick Roth iD, Thierry Gorlia, Jaap C Reijneveld, Filip de Vos, Ahmed Idbaih iD, Jean-Sébastien Frenel, Emilie Le Rhun iD, Juan Manuel Sepulveda, James Perry, G Laura Masucci, Pierre Freres, Hal Hirte und 18 weitere

Neuro-Oncology · 05.09.2024 · 26 (9) · 1670-1682

DOI: 10.1093/neuonc/noae053 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Neuro-Oncology, online erschienen am 19.03.2024. Verfasst von Patrick Roth und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Brain Tumor Center, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Lactones, Temozolomide. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood–brain barrier.

Methods

European Organisation for Research and Treatment of Cancer 1709/Canadian Cancer Trials Group CE.8 was a multicenter, randomized, controlled, open-label phase 3 superiority trial. Key eligibility criteria included newly diagnosed glioblastoma, age > 18 years and Karnofsky performance status > 70. Patients were randomized in a 1:1 ratio. The primary objective was to compare overall survival (OS) in patients receiving marizomib in addition to TMZ/RT→TMZ with patients receiving the only standard treatment in the whole population and in the subgroup of patients with MGMT promoter-unmethylated tumors.

Results

The trial was opened at 82 institutions in Europe, Canada, and the U.S. A total of 749 patients (99.9% of the planned 750) were randomized. OS was not different between the standard and the marizomib arm (median 17 vs. 16.5 months; HR = 1.04; P = .64). PFS was not statistically different either (median 6.0 vs. 6.3 months; HR = 0.97; P = .67). In patients with MGMT promoter-unmethylated tumors, OS was also not different between standard therapy and marizomib (median 14.5 vs. 15.1 months, HR = 1.13; P = .27). More CTCAE grade 3/4 treatment-emergent adverse events were observed in the marizomib arm than in the standard arm.

Conclusions

Adding marizomib to standard temozolomide-based radiochemotherapy resulted in more toxicity, but did not improve OS or PFS in patients with newly diagnosed glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsLactonesTemozolomideHumansMaleMiddle AgedFemaleAgedAdultPyrrolesSurvival RateDNA Repair EnzymesFollow-Up StudiesDNA Modification MethylasesChemoradiotherapyPrognosisAntineoplastic Combined Chemotherapy ProtocolsYoung Adult

Stichwörter der Autor:innen

EORTC 1709MGMTgliomaproteasome inhibitorrandomized study

Substanzen

LactonesTemozolomidemarizomibPyrrolesDNA Repair EnzymesDNA Modification Methylases

Autor:innen und Institutionen

  • Department of Neurology and Brain Tumor Center, University Hospital Zurich, Zurich, Switzerland.
  • Department of Neurology, University of Zurich, Zurich, Switzerland.
  • European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Department of Neurology & Brain Tumor Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Department of Medical Oncology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
  • Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neurologie 2-Mazarin, Paris, France.

ORCID-Profile: Patrick Roth, Ahmed Idbaih, Emilie Le Rhun, Garth Nicholas, Carmen Balana, Matthias Preusser, Michael Weller

Förderung

  • NCI NIH HHS

Zitieren

APA

Roth, P., Gorlia, T., Reijneveld, J. C., de Vos, F., Idbaih, A., Frenel, J. S., Le Rhun, E., Sepulveda, J. M., Perry, J., Masucci, G. L., Freres, P., Hirte, H., Seidel, C., Walenkamp, A., Lukacova, S., Meijnders, P., Blais, A., Ducray, F., Verschaeve, V., …, & Weller, M. (2024). Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. Neuro-Oncology, 26(9), 1670-1682. https://doi.org/10.1093/neuonc/noae053

Vancouver

Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, et al. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. Neuro-Oncology. 2024;26(9):1670-1682. doi:10.1093/neuonc/noae053

BibTeX
@article{Roth2024,
  author = {Roth, Patrick and Gorlia, Thierry and Reijneveld, Jaap C and de Vos, Filip and Idbaih, Ahmed and Frenel, Jean-Sébastien and Le Rhun, Emilie and Sepulveda, Juan Manuel and Perry, James and Masucci, G Laura and Freres, Pierre and Hirte, Hal and Seidel, Clemens and Walenkamp, Annemiek and Lukacova, Slavka and Meijnders, Paul and Blais, Andre and Ducray, Francois and Verschaeve, Vincent and Nicholas, Garth and Balana, Carmen and Bota, Daniela A and Preusser, Matthias and Nuyens, Sarah and Dhermain, Fréderic and van den Bent, Martin and O'Callaghan, Chris J and Vanlancker, Maureen and Mason, Warren and Weller, Michael},
  title = {Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {1670--1682},
  doi = {10.1093/neuonc/noae053}
}
Kostenlos starten →